Latest news and updates from the Health Technology sector.
Dyne Therapeutics Inc. (NASDAQ:DYN) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).
A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) drug class lower and hitting Amgen (NASDAQ:AMGN) harder than any large-cap peer in Tuesday trading.
Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapies for the tough-to-treat rare disease.
Biopharma stocks are dominating the unusual options volume list today, after a high-profile clinical trial failure from Novartis AG (NYSE:NVS) sent shockwaves through the sector.
Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR study evaluating the drug in myotonic dystrophy type 1. The study did not show a statisticall...
Shares of Novartis (NVS) are experiencing a significant decline due to failures in primary endpoints for pelacarsen and del-desiran, along with recent safety co
U.S.-listed shares of Novartis are slumping Tuesday morning following disappointing clinical trial results from the Swiss drugmaker.
Amgen (AMGN) shares sold off after Novartis (NVS) failed to meet its primary endpoint in phase-3 trials. Diane King Hall offers more insight into the volatile moves in the healthcare space.
Novartis shares plunged after late-stage failures of pelacarsen and del-desiran, impacting its long-term growth outlook. Despite setbacks, Novartis reiterated 2025-2030 revenue growth guidance of 5-6% CAGR, aided by Rhapsido's phase 3 success in R...
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
Sandoz CEO Richard Saynor warned U.S. patients could ultimately bear the cost of threatened tariffs on imported generic drugs. Saynor said manufacturers facing steep tariffs could be forced to raise prices or stop supplying some medicines.
U.S. stock futures were lower this morning, with the Dow futures falling over 400 points on Tuesday.
On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history.
Novartis shares fell sharply on Tuesday after the Swiss drugmaker said its experimental treatment for myotonic dystrophy failed in a late-stage clinical trial, marking another setback for a pipeline that investors had been counting on to drive fut...
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug del-desiran's impact on myotonic dystrophy, a form of muscle wasting, had not met its target on a key metric, but reaffirmed its sales guidance through 2030.
The drug candidate was one of three therapies the Swiss pharmaceutical company added to its pipeline through its $12 billion acquisition of Avidity Biosciences.
Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.
Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
BEIJING, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (NASDAQ: HAO; "we" or the "Company"), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.0000001 per share (...
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Holz framed the logic bluntly. “If you take these two companies and you slash expenses, that would be the main thing here.
As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.
Bristol-Myers Squibb (BMY) stock is declining this morning, reversing its premarket gains as Wall Street digests bombshell reports of a potential transatlantic merger with AstraZeneca (AZN). According to media reports, the UK healthcare heavyweigh...
Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.
Geopolitical relief triggered a sharp selloff in oil and a Treasury retreat, handing bulls an opening to reclaim momentum at the start of August, but a surprise move from MicroStrategy and a potential $400 billion pharma megadeal are reshaping the...
Stock futures are pointing to a higher open to kick off August trading as investors look ahead to a packed week of earnings reports; oil prices are tumbling after the U.S. paused strikes on Iran over the weekend; SpaceX is due to reports earnings ...
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in the FTSE 100, as analysts struggled to explain why...
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Monday.
BMY and AZN reportedly talk of a merger, stocks rebound as jobs print approaches, and more